(Q45128200)

English

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial

scientific article published in January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial (English)

1 reference

Europe PubMed Central

9 December 2017

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

expanded access

1 reference

based on heuristic

inferred from title

author name string

Jeha S

1

1 reference

Europe PubMed Central

9 December 2017

Kantarjian H

2

1 reference

Europe PubMed Central

9 December 2017

Irwin D

3

1 reference

Europe PubMed Central

9 December 2017

Shen V

4

1 reference

Europe PubMed Central

9 December 2017

Shenoy S

5

1 reference

Europe PubMed Central

9 December 2017

Blaney S

6

1 reference

Europe PubMed Central

9 December 2017

Camitta B

7

1 reference

Europe PubMed Central

9 December 2017

Pui CH

8

1 reference

Europe PubMed Central

9 December 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

19

1 reference

Europe PubMed Central

9 December 2017

34-38

1 reference

Europe PubMed Central

9 December 2017

1

1 reference

Europe PubMed Central

9 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403566

0 references

Tumor lysis syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA: USE OF ALOPURINOL, A XANTHINE OXIDASE INHIBITOR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

Rasburicase: a potent uricolytic agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

Renal tubular damage in rasburicase: risks of alkalinisation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)--results of the UKCCSG 9003 protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

21 January 2018

Acute tumor lysis syndrome in solid tumors--a case report and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

7 January 2021

based on heuristic

inferred from DOI database lookup

Urinary Xanthine Stones-a Rare Complication of Allopurinol Therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

7 January 2021

based on heuristic

inferred from DOI database lookup

Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

7 January 2021

based on heuristic

inferred from DOI database lookup

Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403566

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403566

1 reference

Europe PubMed Central

9 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

9 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45128200&oldid=2066511196"